Complement System

The complement system is a complex network of more than 30 circulating proteins, primarily synthesized in the liver, that serves as a critical component of the innate immune system. It functions as a biochemical cascade, where the activation of one protein triggers the sequential activation of others, amplifying a response to pathogens. The primary objective of the complement system is to assist (or "complement") the action of antibodies and phagocytic cells to clear pathogens from an organism's bloodstream, connective tissues, and organs. The system is essential for the survival of vertebrates, providing a rapid, non-specific first line of defense that does not require prior exposure to a pathogen, unlike the adaptive immune response. By tagging foreign cells for destruction (opsonization), recruiting inflammatory cells to the site of infection (chemotaxis), and directly punching holes in bacterial membranes (lysis), the complement system prevents systemic infections and aids in the removal of apoptotic cells and immune complexes. Dysregulation of the complement system can lead to severe pathological conditions. Under-activation may result in increased susceptibility to pyogenic infections or the accumulation of immune complexes, leading to autoimmune diseases like systemic lupus erythematosus (SLE). Conversely, over-activation or a failure in the regulatory proteins can cause damage to host tissues, manifesting as hereditary angioedema or atypical hemolytic uremic syndrome (aHUS).

Activation Pathways

The complement system is activated through three distinct biochemical pathways, each recognizing different molecular patterns. Regardless of the initiation method, all three pathways converge at the cleavage of C3, the most abundant complement protein.

The classical pathway is typically triggered by the formation of antigen-antibody complexes. When an antibody (IgM or IgG) binds to a surface antigen, the C1 complex (consisting of C1q, C1r, and C1s) binds to the Fc region of the antibody. This initiates a proteolytic cascade: C1s cleaves C4 and C2, forming the C3 convertase ($C4b2a$), which then cleaves C3 into C3a and C3b.

The lectin pathway is independent of antibodies. It is initiated when soluble pattern recognition receptors (PRRs), such as mannose-binding lectin (MBL) or ficolins, recognize specific carbohydrate patterns (like mannose) on the surface of bacteria or fungi. These proteins activate MBL-associated serine proteases (MASPs), which, like the classical pathway, lead to the formation of the C3 convertase ($C4b2a$).

The alternative pathway acts as a "surveillance" system. It is characterized by the spontaneous hydrolysis of C3 in the plasma, a process known as "tick-over." This creates a small amount of C3($\text{H}_2\text{O}$), which can bind Factor B. Once Factor B is cleaved by Factor D, the resulting complex ($C3bBb$) acts as the alternative C3 convertase. This pathway is unique because it can amplify the responses initiated by the other two pathways, creating a positive feedback loop.

Effector Functions

Once the C3 convertase is formed, the system executes three primary effector functions that neutralize the threat.

The cleavage of C3 produces C3b, which covalently attaches to the surface of the pathogen. C3b acts as an "opsonin"—a molecular tag. Phagocytic cells, such as macrophages and neutrophils, possess C3b receptors. When these cells encounter a C3b-coated pathogen, they bind to the tag and engulf the microbe via phagocytosis.

The small fragments released during activation, specifically C3a and C5a, are known as anaphylatoxins. These molecules bind to receptors on mast cells and basophils, triggering the release of histamine. This increases vascular permeability and attracts other leukocytes to the site of infection, facilitating a robust inflammatory response.

The final stage of the complement cascade is the formation of the Membrane Attack Complex. C5 convertase cleaves C5 into C5a and C5b. C5b recruits C6, C7, and C8, which then catalyze the polymerization of multiple C9 molecules. These C9 proteins form a transmembrane pore in the target cell membrane. The resulting hole disrupts the osmotic balance of the cell, leading to an influx of water and ions, which causes the cell to swell and lyse.

Regulation and Control

Because the complement system is potentially destructive to host tissues, it is strictly regulated by a variety of soluble and membrane-bound proteins. These regulators prevent the "innocent bystander" effect, where healthy host cells are accidentally lysed.

• C1 Inhibitor (C1-INH): Dissociates C1r and C1s from C1q, halting the classical pathway. A deficiency in C1-INH leads to hereditary angioedema.

• Factor H: The primary regulator of the alternative pathway. It competes with Factor B for binding to C3b and accelerates the decay of the $C3bBb$ complex.

• CD59 (Protectin): A membrane protein that prevents the final polymerization of C9, thereby protecting host cells from the formation of the MAC.

• DAF (Decay-Accelerating Factor): Found on the surface of host cells, it rapidly dissociates C3 convertases, ensuring the cascade does not propagate on self-surfaces.

Clinical Significance and Therapeutics

Understanding the complement system has led to significant breakthroughs in treating autoimmune and inflammatory diseases.

Genetic deficiencies in specific complement proteins correlate with distinct clinical phenotypes. For example, individuals lacking C2 or C4 are at a significantly higher risk for developing systemic lupus erythematosus (SLE) due to an inability to clear immune complexes. Deficiencies in the late-stage components (C5-C9) often lead to recurrent infections by Neisseria species, as the MAC is essential for killing these bacteria.

Pharmacological targeting of the complement system is a growing field in precision medicine. Monoclonal antibodies and small molecule inhibitors are now used to treat rare diseases. For instance, Eculizumab is a humanized monoclonal antibody that binds to C5, preventing the formation of the MAC and the release of C5a. This drug is used to treat Paroxysmal Nocturnal Hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).

See also

• Innate Immunity
• Opsonization
• Major Histocompatibility Complex
• Cytokines

References